Analyzing Ratios: Gain Therapeutics Inc (GANX)’s Financial Story Unveiled

Ulysses Smith

The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.

The price of Gain Therapeutics Inc (NASDAQ: GANX) closed at $1.87 in the last session, up 3.31% from day before closing price of $1.81. In other words, the price has increased by $3.31 from its previous closing price. On the day, 0.67 million shares were traded. GANX stock price reached its highest trading level at $1.895 during the session, while it also had its lowest trading level at $1.74.

Ratios:

We take a closer look at GANX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.79 and its Current Ratio is at 1.79. In the meantime, Its Debt-to-Equity ratio is 0.18 whereas as Long-Term Debt/Eq ratio is at 0.11.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Scotiabank on March 07, 2025, initiated with a Sector Outperform rating and assigned the stock a target price of $12.

On December 06, 2024, ROTH MKM started tracking the stock assigning a Buy rating and target price of $7.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GANX now has a Market Capitalization of 67223896 and an Enterprise Value of 61210396.

Stock Price History:

The Beta on a monthly basis for GANX is 0.11, which has changed by -0.3297491 over the last 52 weeks, in comparison to a change of 0.13837254 over the same period for the S&P500. Over the past 52 weeks, GANX has reached a high of $3.19, while it has fallen to a 52-week low of $1.41. The 50-Day Moving Average of the stock is 4.40%, while the 200-Day Moving Average is calculated to be -2.41%.

Shares Statistics:

According to the various share statistics, GANX traded on average about 582.07K shares per day over the past 3-months and 1208620 shares per day over the past 10 days. A total of 35.95M shares are outstanding, with a floating share count of 34.19M. Insiders hold about 4.90% of the company’s shares, while institutions hold 10.54% stake in the company. Shares short for GANX as of 1759190400 were 422327 with a Short Ratio of 0.73, compared to 1756425600 on 233336. Therefore, it implies a Short% of Shares Outstanding of 422327 and a Short% of Float of 1.2200001.

Earnings Estimates

Currently, 3.0 analysts are dedicated to thoroughly evaluating and rating the performance of Gain Therapeutics Inc (GANX) in the stock market.The consensus estimate for the next quarter is -$0.16, with high estimates of -$0.15 and low estimates of -$0.18.

Analysts are recommending an EPS of between -$0.65 and -$0.69 for the fiscal current year, implying an average EPS of -$0.67. EPS for the following year is -$0.63, with 4.0 analysts recommending between -$0.35 and -$0.82.

DwinneX
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.